Data gathered: December 28
Alternative Data for MoonLake Immunotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 75 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 568 | Sign up | Sign up | Sign up |
| Twitter Followers | 108 | Sign up | Sign up | Sign up |
| Twitter Mentions | 10 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 95 | Sign up | Sign up | Sign up |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
| Price | $55.37 |
| Target Price | Sign up |
| Volume | 134,230 |
| Market Cap | $3.43B |
| Year Range | $38.43 - $56.3 |
| Dividend Yield | 0% |
| Analyst Rating | 91% buy |
| Industry | Biotechnology |
In the news
 |
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 5.1% – Here’s What HappenedDecember 28 - ETF Daily News |
|
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $81.43 Average PT from BrokeragesDecember 20 - ETF Daily News |
|
Wellington Management Group LLP Sells 180,599 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)December 16 - ETF Daily News |
 |
MoonLake Immunotherapeutics: A Somewhat Complicated StoryNovember 20 - SeekingAlpha |
|
US Bancorp DE Buys Shares of 869 MoonLake Immunotherapeutics (NASDAQ:MLTX)November 18 - ETF Daily News |
 |
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisNovember 12 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 7.4M | -7.4M | -35M | -36M | -0.560 |
| Q2 '24 | 0 | 6.9M | -7M | -24M | -31M | -0.390 |
| Q1 '24 | 20,000 | 6.8M | -6.9M | -14M | -20M | -0.220 |
| Q4 '23 | 430,000 | 6.9M | -6.5M | -7.4M | -15M | -0.120 |
| Q3 '23 | 0 | 5.4M | -5.9M | -9.4M | -13M | -0.180 |
Insider Transactions View All
| BIOTECHNOLOGY VALUE FUND L P filed to sell 1,287,768 shares at $50. October 8 '24 |
| BIOTECHNOLOGY VALUE FUND L P filed to sell 8,168,838 shares at $50. October 8 '24 |
| Sturge Simon filed to sell 171,980 shares at $53.7. October 8 '24 |
| BIOTECHNOLOGY VALUE FUND L P filed to sell 10,235,089 shares at $50. October 8 '24 |
| Santos Da Silva Jorge filed to sell 2,982,814 shares at $55.9. February 29 '24 |
Similar companies
Read more about MoonLake Immunotherapeutics (MLTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of MoonLake Immunotherapeutics?
The Market Cap of MoonLake Immunotherapeutics is $3.43B.
What is the current stock price of MoonLake Immunotherapeutics?
Currently, the price of one share of MoonLake Immunotherapeutics stock is $55.37.
How can I analyze the MLTX stock price chart for investment decisions?
The MLTX stock price chart above provides a comprehensive visual representation of MoonLake Immunotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling MoonLake Immunotherapeutics shares. Our platform offers an up-to-date MLTX stock price chart, along with technical data analysis and alternative data insights.
Does MLTX offer dividends to its shareholders?
As of our latest update, MoonLake Immunotherapeutics (MLTX) does not offer dividends to its shareholders. Investors interested in MoonLake Immunotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of MoonLake Immunotherapeutics?
Some of the similar stocks of MoonLake Immunotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.